An observational study in Postoperative Pulmonary Complications (PPCs), sponsored by General Hospital of Ningxia Medical University. Enrolling by invitation at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by General Hospital of Ningxia Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Background and Objective Postoperative pulmonary complications (PPCs) are common after elective colorectal surgery and are associated with prolonged hospitalization, increased morbidity, and delayed recovery. Existing PPC prediction tools were mainly developed in thoracic or mixed surgical populations and rely predominantly on clinical variables; preoperative chest CT information remains underused, and a population-specific tool for elderly colorectal cancer patients is still lacking. This study aims to develop and validate a multimodal deep learning model that integrates preoperative chest CT-derived features with multidimensional clinical variables to predict PPCs in patients aged ≥65 years undergoing elective radical colorectal cancer surgery, and to quantify its incremental value and clinical net benefit.
Methods This is a single-center retrospective cohort study. Eligible patients will be assigned to a development window (August 2020-August 2024), split chronologically at a 7∶1∶2 ratio into training, validation, and test sets with five-fold cross-validation, and a locked temporal external validation window (September 2024-September 2026), which will be used only after the final model is fixed. The primary outcome is 30-day composite PPCs defined according to the EPCO criteria; the Melbourne Group Scale will serve as a parallel sensitivity definition. Preoperative clinical variables and chest CT images obtained within four weeks before surgery will be collected. A convolutional neural network imaging branch-or 2D transfer learning based on RadImageNet if the sample size is insufficient-will extract CT deep features, which will be fused with clinical variables at the feature (intermediate) level. Six classifiers, including logistic regression, support vector machine, random forest, XGBoost, LightGBM, and multilayer perceptron, will be tuned within a unified search space. Discrimination (AUC with DeLong test and Bootstrap 95% CI), calibration (calibration curves, Brier score), incremental value (NRI, IDI), and clinical utility (decision curve analysis) will be evaluated against the ARISCAT and GSU-Pulmonary scores, a clinical-only model, and an imaging-only model. Grad-CAM and SHAP will be applied to interpret the model.
Expected Outcome The study is expected to provide an interpretable and deployable preoperative risk stratification tool for elderly patients undergoing colorectal surgery, clarify the incremental contribution of preoperative chest CT information, and define the threshold range in which the model yields net clinical benefit.
General Hospital of Ningxia Medical University is the lead sponsor of 111 studies on the registry; 44 are open to participants now.
Counted across the registry records on this site, refreshed daily.
consecutive patients aged ≥65 years undergoing radical resection for colorectal cancer at our hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PPCs within 30 days after surgery
Time frame: from August 2020 to September 2026
Started Aug 2026 (actual). Primary completion is estimated for Jun 2028, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
General Hospital of Ningxia Medical University →